Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Stellar 177% Return Over the Last Five Years
When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?
S&P 500 Futures Drop In Premarket Trading; Intra-Cellular Therapies, Avantor Lag
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
